Heron Therapeuti logo
HRTXHeron Therapeuti
Trade HRTX now
Heron Therapeuti primary media

About Heron Therapeuti

Heron Therapeutics (NASDAQ:HRTX) specializes in developing innovative treatments aimed at addressing unmet medical needs in pain management and oncology. Their portfolio includes advanced therapeutics designed to improve the lives of patients undergoing surgery or those facing challenging cancer treatments. Heron is dedicated to pushing the boundaries of science to create solutions that can significantly enhance patient care and outcomes. Their objectives focus on advancing their research and development pipeline, ensuring the accessibility of their therapies, and maintaining a strong commitment to ethical practices and sustainability in all their operations.

What is HRTX known for?

Snapshot

Public US
Ownership
1983
Year founded
181
Employees
San Diego, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Heron Therapeuti

  • CINVANTI for chemotherapy-induced nausea and vomiting
  • ZYNRELEF for postoperative pain management
  • SUSTOL for delayed chemotherapy-induced nausea and vomiting
  • HTX-011 for postoperative pain
  • APF530 for chemotherapy-induced nausea and vomiting prevention
  • HTX-034 for postoperative pain management

equipe executiva do Heron Therapeuti

  • Mr. Craig Alexander CollardCEO & Director
  • Ms. Ira DuarteExecutive VP & CFO
  • Dr. William P. Forbes Pharm. D., Pharm.D.Executive VP & Chief Development Officer
  • Mr. Mark E. HensleyExecutive VP & COO
  • Melissa JarelExecutive Director of Legal
  • Mr. Ryan CraigVice President of Marketing
  • Mr. John AikenExecutive Director of People Management & Training
  • Dr. John C. Arthur Ph.D.Senior Vice President of Manufacturing & Supply
  • Mr. Robert SullivanSenior Vice President of Oncology Care Franchise & Commercial Operations
  • Mr. Brett FleshmanChief Business Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.